TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05726773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Therapy
Description: In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
Study: NCT05154994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT06542757

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1.5 T Elekta Unity MR-Linac system
Description: Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel rectal spacer (SpaceOAR)
Description: A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.
Study: NCT05006781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration
Study: NCT05633784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleassistance
Description: Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Support from a physiotherapist (if needed)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telepsycology
Description: Psychological support (if necessary)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life
Description: Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biochemistry evaluation
Description: Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biochemistry evaluation
Description: Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: 6-minute-walking test, IMC, NYHA class, Ejection fraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: 6-minute-walking test, IMC, NYHA class, Ejection fraction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: State of health of the patient
Description: Severity Index and Comordbidity index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State of health of the patient
Description: Severity Index and Comordbidity index
Study: NCT05219201

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).
Study: NCT05106140

Intervention type: DEVICE
Intervention: Kinarm Robotic Exoskeleton Assessment
Description: The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours.

Intervention type: OTHER
Intervention: Clinical Assessment
Description: The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
Study: NCT05219201

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: partial-body cryotherapy chamber session
Description: The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).
Study: NCT04720417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raf/MEK Inhibitor VS-6766
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT05404529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study: NCT05106140

Intervention type: OTHER
Intervention: Clinical Assessment
Description: The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
Study: NCT04675073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia substrate-based radiofrequency ablation
Description: The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
Study: NCT05408130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device
Description: All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device
Description: In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
Study: NCT05219773

Intervention type: DEVICE
Group type: OTHER
Intervention: NuvoAir Air Next spirometer
Description: * The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey.
Study: NCT00610051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprostadil
Description: central venous access continuous delivery with 500mcg/48 hours in active arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil
Description: central venous access continuous delivery with 500mcg/48 hours in active arm
Study: NCT06175494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Description: boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Description: boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: boost with saline
Study: NCT05792553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonded tongue tamers
Description: Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized bonded spurs
Description: Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
Study: NCT05938335

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: sequencing of a panel of 14 genes in leptin melanocortin pathway
Description: sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
Study: NCT04352036

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study: NCT05792553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional fixed palatal spurs
Description: conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
Study: NCT05668715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
Study: NCT06533124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.
Description: In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
Study: NCT04741139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Diphenhydramine Only Product
Description: Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
Study: NCT04901871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02 mg/kg, age<65
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.07 mg/kg, age<65
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12 mg/kg, age<65
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.17 mg/kg, age<65
Description: Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.22 mg/kg, age<65
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.27 mg/kg, age<65
Description: Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02 mg/kg, age≥65
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.07 mg/kg, age≥65
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12 mg/kg, age≥65
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
Study: NCT05174988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angle stitch
Description: Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
Study: NCT04901871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.17 mg/kg, age≥65
Description: Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
Study: NCT06108063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 12.5 mg oral Losartan taken for 28 days total (4 week postoperative).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Losartan
Description: Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
Study: NCT05550246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Treatment given for 3 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Treatment given for 3 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Treatment given for 3 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Treatment given for 3 nights
Study: NCT06531356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous amniotic fluid
Description: 10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No amniotic fluid injected in skin edges
Description: conventional closure of skin
Study: NCT05972447

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate implant placement of Ultrawide diameter dental implants
Description: immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
Study: NCT04901871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.22 mg/kg, age≥65
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
Study: NCT04712526

Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler
Study: NCT04933682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral capsule.
Study: NCT06535984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise+Swaddling
Description: White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
Study: NCT06536114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries
Description: The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
Study: NCT04901871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.27 mg/kg, age≥65
Description: Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
Study: NCT06365151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy
Description: osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham osteopathic manual therapy
Description: a sham osteopathic manual treatment without therapeutic effect
Study: NCT06386484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PolarCap System
Description: The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
Study: NCT05675345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC only
Description: HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC + CNEP10
Description: HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%